CN113755596A - Kit for detecting gene mutation of laryngeal squamous cell carcinoma radiotherapy sensitivity related gene ATM and ATR and application thereof - Google Patents
Kit for detecting gene mutation of laryngeal squamous cell carcinoma radiotherapy sensitivity related gene ATM and ATR and application thereof Download PDFInfo
- Publication number
- CN113755596A CN113755596A CN202111190928.7A CN202111190928A CN113755596A CN 113755596 A CN113755596 A CN 113755596A CN 202111190928 A CN202111190928 A CN 202111190928A CN 113755596 A CN113755596 A CN 113755596A
- Authority
- CN
- China
- Prior art keywords
- gene
- score
- laryngeal squamous
- prodh
- vstm2l
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
- G16B20/50—Mutagenesis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- General Health & Medical Sciences (AREA)
- Urology & Nephrology (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Physics & Mathematics (AREA)
- Hospice & Palliative Care (AREA)
- Biophysics (AREA)
- Cell Biology (AREA)
- Medicinal Chemistry (AREA)
- Oncology (AREA)
- Food Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Computational Biology (AREA)
- Evolutionary Biology (AREA)
- Medical Informatics (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Theoretical Computer Science (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
The invention relates to the technical field of molecular diagnosis, in particular to a kit for detecting gene mutation of genes related to radiotherapy sensitivity ATM and ATR of laryngeal squamous cell carcinoma and application thereof, wherein the kit comprises reagents for detecting expression levels of VSTM2L, TSPAN8, RDH10, PRODH, PITX2, ODC1, MASP1, KLHDC8A, GPRC5D, CTAG2, CCL26 and ABCA 13. The invention screens the genes related to ATM and ATR mutation by RNA sequencing, LASSO and binary Logistic regression, constructs Score, obtains the corresponding threshold value of the Score in the laryngeal squamous cell carcinoma by ROC analysis, and can be used for predicting the ATM and ATR gene mutation in the laryngeal squamous cell carcinoma. According to the invention, the specific gene mutation related to the sensitivity of laryngeal squamous cell carcinoma radiotherapy is predicted by utilizing the expression quantity of the genome composition, and the detection method has the advantages of simplicity and convenience in operation, high accuracy and good specificity and has a good application prospect.
Description
Technical Field
The invention relates to the technical field of molecular diagnosis, in particular to a kit for detecting gene mutation of genes related to sensitivity of radiotherapy of laryngeal squamous cell carcinoma (ATM) and ATR (attenuated total reflectance) and application thereof.
Background
Laryngeal cancer is a high-grade tumor of the head and neck, while squamous cell carcinoma is its most common type of pathology. Radiotherapy is one of the main treatment methods of laryngeal squamous cell carcinoma, and has very good treatment effect on most laryngeal squamous cell carcinoma patients. However, in some patients with laryngeal cancer, the effect of radiotherapy is not good. If the radiotherapy sensitivity of the tumor of the patient can be judged as early as possible, whether the patient is suitable for radiotherapy can be accurately judged, so that the clinical practice is guided, the prognosis of the patient is greatly improved, and unnecessary cost of the patient and waste of medical resources are reduced.
ATM (ataxia telangiectasia-mutated) and ATR (ATM and Rad3 related) are the most apical sites in DNA damage repair, which is the key contributor to the killing of tumor cells by radiation. ATM and ATR have phosphorylation kinase activity, and are subjected to DNA chain breakage during cell radiation damage, so that the expression is increased and rapidly activated, and the corresponding sites of downstream target proteins are acted, thereby causing cell cycle arrest and DNA repair. When ATM or ATR has mutation, cells can not repair DNA damaged by radiotherapy in time, so the radiotherapy sensitivity is higher. The detection of related ATM and ATR mutations has important significance for judging whether patients are suitable for receiving radiotherapy.
The specific method and kit for detecting the ATM/ATR gene mutation in laryngeal squamous cell carcinoma adopted in the invention are not reported at present. At present, the detection of the gene mutation of the laryngeal squamous cell carcinoma ATM and ATR is not a clinical routine project, the independent detection is expensive, and the development of a new detection kit has great research value.
Disclosure of Invention
The invention aims to provide a kit for detecting gene mutation of genes related to radiotherapy sensitivity of laryngeal squamous cell carcinoma (ATM) and ATR (attenuated total reflectance) and application thereof aiming at the defects in the prior art.
In a first aspect, the invention provides an application of an agent for detecting VSTM2L, TSPAN8, RDH10, PRODH, PITX2, ODC1, MASP1, KLHDC8A, GPRC5D, CTAG2, CCL26 and ABCA13 genes or protein expression amount in preparing a kit for predicting whether an individual or a sample of laryngeal squamous cell carcinoma has ATM and/or ATR gene mutation.
As a preferable example, the reagent for detecting the gene or protein expression amount of VSTM2L, TSPAN8, RDH10, PRODH, PITX2, ODC1, MASP1, KLHDC8A, GPRC5D, CTAG2, CCL26 and ABCA13 is a gene-specific primer, a gene-specific probe or an antibody.
As another preferred example, the kit comprises instructions, which are recorded with the following:
detecting log2(FPKM +1) values for VSTM2L, TSPAN8, RDH10, PRODH, PITX2, ODC1, MASP1, KLHDC8A, GPRC5D, CTAG2, CCL26, and ABCA13 gene expression levels in a tumor tissue sample from an individual with laryngeal squamous carcinoma;
substituting the above values into the Score model Score (-0.7519 × VSTM2L) + (-0.7602 × TSPAN8) + (0.1142 × RDH10) + (0.1816 × PRODH) + (0.3597 × PITX2) + (0.0034 × ODC1) + (-0.3224 × MASP1) + (0.4007 × KLHDC8A) + (0.0877 × GPRC5D) + (0.1375 × CTAG2) + (-0.9765 × CCL26) + (0.4486 × ABCA13) +7.047 to calculate the Score;
when the Score is not less than 0, the laryngeal squamous carcinoma individual or sample is considered to have no ATM and/or ATR gene mutation; when Score <0, ATM and/or ATR gene mutation is present on the individual or sample representative of laryngeal squamous carcinoma.
In a second aspect, the invention provides application of an agent for detecting VSTM2L, TSPAN8, RDH10, PRODH, PITX2, ODC1, MASP1, KLHDC8A, GPRC5D, CTAG2, CCL26 and ABCA13 genes or protein expression amount in preparation of a kit for predicting radiotherapy sensitivity of individuals with laryngeal squamous cell carcinoma.
As a preferable example, the reagent for detecting the gene or protein expression amount of VSTM2L, TSPAN8, RDH10, PRODH, PITX2, ODC1, MASP1, KLHDC8A, GPRC5D, CTAG2, CCL26 and ABCA13 is a gene-specific primer, a gene-specific probe or an antibody.
As another preferred example, the kit comprises instructions, which are recorded with the following:
detecting log2(FPKM +1) values for VSTM2L, TSPAN8, RDH10, PRODH, PITX2, ODC1, MASP1, KLHDC8A, GPRC5D, CTAG2, CCL26, and ABCA13 gene expression levels in a tumor tissue sample from an individual with laryngeal squamous carcinoma;
substituting the above values into the Score model Score (-0.7519 × VSTM2L) + (-0.7602 × TSPAN8) + (0.1142 × RDH10) + (0.1816 × PRODH) + (0.3597 × PITX2) + (0.0034 × ODC1) + (-0.3224 × MASP1) + (0.4007 × KLHDC8A) + (0.0877 × GPRC5D) + (0.1375 × CTAG2) + (-0.9765 × CCL26) + (0.4486 × ABCA13) +7.047 to calculate the Score;
if the Score is more than or equal to 0, the laryngeal squamous carcinoma individual is considered to be sensitive to radiotherapy; when Score <0, the individual with laryngeal squamous carcinoma was represented as insensitive to radiation therapy.
In a third aspect, the invention provides a kit for predicting the presence or absence of ATM and/or ATR gene mutation in an individual or sample of laryngeal squamous carcinoma, wherein the kit comprises reagents for detecting VSTM2L, TSPAN8, RDH10, PRODH, PITX2, ODC1, MASP1, KLHDC8A, GPRC5D, CTAG2, CCL26 and ABCA13 genes or protein expression levels.
As a preferable example, the reagent for detecting the gene or protein expression amount of VSTM2L, TSPAN8, RDH10, PRODH, PITX2, ODC1, MASP1, KLHDC8A, GPRC5D, CTAG2, CCL26 and ABCA13 is a gene-specific primer, a gene-specific probe or an antibody.
As another preferred example, the kit comprises instructions, which are recorded with the following:
detecting log2(FPKM +1) values of VSTM2L, TSPAN8, RDH10, PRODH, PITX2, ODC1, MASP1, KLHDC8A, GPRC5D, CTAG2, CCL26, and ABCA13 gene expression levels in individuals or samples of laryngeal squamous cell carcinoma;
substituting the above values into the Score model Score (-0.7519 × VSTM2L) + (-0.7602 × TSPAN8) + (0.1142 × RDH10) + (0.1816 × PRODH) + (0.3597 × PITX2) + (0.0034 × ODC1) + (-0.3224 × MASP1) + (0.4007 × KLHDC8A) + (0.0877 × GPRC5D) + (0.1375 × CTAG2) + (-0.9765 × CCL26) + (0.4486 × ABCA13) +7.047 to calculate the Score;
if the Score is more than or equal to 0, the laryngeal squamous carcinoma individual or the sample is considered to have no ATM and/or ATR gene mutation, and the laryngeal squamous carcinoma individual is sensitive to radiotherapy; when Score <0, ATM and/or ATR gene mutations were present in the laryngeal squamous carcinoma individual or sample, who was not sensitive to radiation therapy.
In a fourth aspect, the invention provides a kit for predicting sensitivity of radiotherapy of an individual with laryngeal squamous cell carcinoma, which comprises reagents for detecting gene or protein expression levels of VSTM2L, TSPAN8, RDH10, PRODH, PITX2, ODC1, MASP1, KLHDC8A, GPRC5D, CTAG2, CCL26 and ABCA 13.
As a preferable example, the reagent for detecting the gene or protein expression amount of VSTM2L, TSPAN8, RDH10, PRODH, PITX2, ODC1, MASP1, KLHDC8A, GPRC5D, CTAG2, CCL26 and ABCA13 is a gene-specific primer, a gene-specific probe or an antibody.
As another preferred example, the kit comprises instructions, which are recorded with the following:
detecting log2(FPKM +1) values of VSTM2L, TSPAN8, RDH10, PRODH, PITX2, ODC1, MASP1, KLHDC8A, GPRC5D, CTAG2, CCL26, and ABCA13 gene expression levels in individuals or samples of laryngeal squamous cell carcinoma;
substituting the above values into the Score model Score (-0.7519 × VSTM2L) + (-0.7602 × TSPAN8) + (0.1142 × RDH10) + (0.1816 × PRODH) + (0.3597 × PITX2) + (0.0034 × ODC1) + (-0.3224 × MASP1) + (0.4007 × KLHDC8A) + (0.0877 × GPRC5D) + (0.1375 × CTAG2) + (-0.9765 × CCL26) + (0.4486 × ABCA13) +7.047 to calculate the Score;
if the Score is more than or equal to 0, the laryngeal squamous carcinoma individual or the sample is considered to have no ATM and/or ATR gene mutation, and the laryngeal squamous carcinoma individual is sensitive to radiotherapy; when Score <0, ATM and/or ATR gene mutations were present in the laryngeal squamous carcinoma individual or sample, who was not sensitive to radiation therapy.
Herein, the related genes can be referred to as Genebank, and the "VSTM 2L" Gene can be referred to as Gene ID: 128434; the "TSPAN 8" Gene can be referred to Gene ID 7103; the "RDH 10" Gene can be referred to Gene ID 157506; "PRODH" Gene can be referred to Gene ID: 5625; the "PITX 2" Gene can be referred to as Gene ID 5308; the "ODC 1" Gene can be referred to Gene ID: 4953; the "MASP 1" Gene can be referred to Gene ID: 5648; the "KLHDC 8A" Gene can be referred to as Gene ID: 55220; the "GPRC 5D" Gene can be referred to Gene ID: 55507; the "CTAG 2" Gene can be referred to Gene ID: 30848; the "CCL 26" Gene can be referred to as Gene ID: 10344; the "ABCA 13" Gene can be referred to as Gene ID: 154664.
The invention has the advantages that:
1. the invention firstly provides that the gene or protein composition of VSTM2L, TSPAN8, RDH10, PRODH, PITX2, ODC1, MASP1, KLHDC8A, GPRC5D, CTAG2, CCL26 and ABCA13 can be used for detecting the mutation of radiotherapy sensitivity related gene ATM/ATR in the tumor tissue of a laryngeal squamous cell carcinoma patient, can effectively guide the individualized treatment of the laryngeal squamous cell carcinoma patient, improve the clinical benefit and avoid the unnecessary waste of medical resources.
2. ATM/ATR gene mutation belongs to an unconventional detection project clinically at present, and the cost for singly detecting the gene mutation is high. The invention can judge whether the laryngeal squamous cell carcinoma patient has the gene mutation or not by the RNA sequencing technology which is widely applied clinically, and has the advantages of economy, high accuracy, good sensitivity and good specificity.
Drawings
FIG. 1 is a Receiver Operating Characteristic (ROC) curve of the prediction model.
FIG. 2 shows 184 differential genes analyzed by the TCGA database.
Detailed Description
The following detailed description of the present invention will be made with reference to the accompanying drawings.
Example 1 Scoring model construction for laryngeal squamous cell carcinoma ATM/ATR mutation
1. Method of producing a composite material
We first obtained 111 laryngeal squamous carcinoma sample data from the TCGA database, divided the samples into a mutation group (n-11) and a wild group (n-100) according to the presence or absence of ATM or ATR gene mutation, and further calculated and screened 184 differential genes. By performing LASSO regression analysis on the expression data [ log2(FPKM +1) form ] of the 184 differential genes described above for 111 samples, we obtained 12 genes that were significantly related to ATM/ATR gene mutation as: VSTM2L, TSPAN8, RDH10, PRODH, PITX2, ODC1, MASP1, KLHDC8A, GPRC5D, CTAG2, CCL26, ABCA 13.
A scoring model (-0.7519 × VSTM2L) + (-0.7602 × TSPAN8) + (0.1142 × RDH10) + (0.1816 × PRODH) + (0.3597 × PITX2) + (0.0034 × ODC1) + (-0.3224 × MASP1) + (0.4007 × KLHDC8A) + (0.0877 × GPRC5D) + (0.1375 × CTAG2) + (-0.9765 × CCL26) + (0.4486 × ABCA13) was constructed by binary Logistic regression.
We calculated a score for each sample based on this scoring model, and obtained the best threshold point from the ROC curve, which was-7.047. This value was integrated into the scoring model to obtain the final scoring model Score (-0.7519 × VSTM2L) + (-0.7602 × TSPAN8) + (0.1142 × RDH10) + (0.1816 × PRODH) + (0.3597 × PITX2) + (0.0034 × ODC1) + (-0.3224 × MASP1) + (0.4007 × KLHDC8A) + (0.0877 × GPRC5D) + (0.1375 × CTAG2) + (-0.9765 × CCL26) + (0.4486 × ABCA13) + 7.047.
The TCGA samples were divided into two groups according to the scoring model, with scores above 0 assigned to the wild group and scores below 0 assigned to the mutant group.
The experimental results show that: the sensitivity of the prediction model was 0.909, and the specificity was 0.960.
Example 2 Effect verification
50 samples of laryngeal squamous cell carcinoma collected at the eye, ear, nose and throat hospitals at the university of Compound Dan were subjected to RNA sequencing and tested for ATM/ATR gene mutations. Substituting the RNA expression data into the prediction model in the embodiment 1 to obtain the Score of each sample, and when the Score of the detected sample is more than or equal to 0, determining that the sample does not have ATM or ATR gene mutation; when the Score of the detected sample is less than 0, the sample represents that the ATM or ATR gene mutation exists. The experimental results show that: the sensitivity of the prediction model is 0.888, and the specificity is 0.927.
The above description is only a preferred embodiment of the present invention, and it should be noted that, for those skilled in the art, several modifications and additions can be made without departing from the method of the present invention, and these modifications and additions should also be regarded as the protection scope of the present invention.
Claims (10)
1. The application of the reagent for detecting VSTM2L, TSPAN8, RDH10, PRODH, PITX2, ODC1, MASP1, KLHDC8A, GPRC5D, CTAG2, CCL26 and ABCA13 genes or protein expression quantity in preparing a kit for predicting whether ATM and/or ATR gene mutation exists in laryngeal squamous cell carcinoma individuals or samples.
2. The use of claim 1, wherein the reagent for detecting the gene or protein expression level of VSTM2L, TSPAN8, RDH10, PRODH, PITX2, ODC1, MASP1, KLHDC8A, GPRC5D, CTAG2, CCL26, and ABCA13 is a gene-specific primer, a gene-specific probe, or an antibody.
3. The use according to claim 1, wherein the kit comprises instructions for carrying out the following:
detecting log2(FPKM +1) values for VSTM2L, TSPAN8, RDH10, PRODH, PITX2, ODC1, MASP1, KLHDC8A, GPRC5D, CTAG2, CCL26, and ABCA13 gene expression levels in a tumor tissue sample from an individual with laryngeal squamous carcinoma;
substituting the above values into the Score model Score (-0.7519 × VSTM2L) + (-0.7602 × TSPAN8) + (0.1142 × RDH10) + (0.1816 × PRODH) + (0.3597 × PITX2) + (0.0034 × ODC1) + (-0.3224 × MASP1) + (0.4007 × KLHDC8A) + (0.0877 × GPRC5D) + (0.1375 × CTAG2) + (-0.9765 × CCL26) + (0.4486 × ABCA13) +7.047 to calculate the Score;
when the Score is not less than 0, the laryngeal squamous carcinoma individual or sample is considered to have no ATM and/or ATR gene mutation; when Score <0, ATM and/or ATR gene mutation is present on the individual or sample representative of laryngeal squamous carcinoma.
4. The application of the reagent for detecting VSTM2L, TSPAN8, RDH10, PRODH, PITX2, ODC1, MASP1, KLHDC8A, GPRC5D, CTAG2, CCL26 and ABCA13 genes or protein expression quantity in preparing a kit for predicting the radiotherapy sensitivity of an individual with laryngeal squamous cell carcinoma.
5. The use of claim 4, wherein the reagent for detecting the gene or protein expression level of VSTM2L, TSPAN8, RDH10, PRODH, PITX2, ODC1, MASP1, KLHDC8A, GPRC5D, CTAG2, CCL26 and ABCA13 is a gene-specific primer, a gene-specific probe or an antibody.
6. The use according to claim 4, wherein the kit comprises instructions bearing the following:
detecting log2(FPKM +1) values for VSTM2L, TSPAN8, RDH10, PRODH, PITX2, ODC1, MASP1, KLHDC8A, GPRC5D, CTAG2, CCL26, and ABCA13 gene expression levels in a tumor tissue sample from an individual with laryngeal squamous carcinoma;
substituting the above values into the Score model Score (-0.7519 × VSTM2L) + (-0.7602 × TSPAN8) + (0.1142 × RDH10) + (0.1816 × PRODH) + (0.3597 × PITX2) + (0.0034 × ODC1) + (-0.3224 × MASP1) + (0.4007 × KLHDC8A) + (0.0877 × GPRC5D) + (0.1375 × CTAG2) + (-0.9765 × CCL26) + (0.4486 × ABCA13) +7.047 to calculate the Score;
if the Score is more than or equal to 0, the laryngeal squamous carcinoma individual is considered to be sensitive to radiotherapy; when Score <0, the individual with laryngeal squamous carcinoma was represented as insensitive to radiation therapy.
7. A kit for predicting whether ATM and/or ATR gene mutation exists in an individual or a sample of laryngeal squamous carcinoma, wherein the kit consists of reagents for detecting VSTM2L, TSPAN8, RDH10, PRODH, PITX2, ODC1, MASP1, KLHDC8A, GPRC5D, CTAG2, CCL26 and ABCA13 genes or protein expression quantity.
8. A kit for predicting radiotherapy sensitivity of an individual with laryngeal squamous carcinoma, which is characterized by consisting of reagents for detecting gene or protein expression levels of VSTM2L, TSPAN8, RDH10, PRODH, PITX2, ODC1, MASP1, KLHDC8A, GPRC5D, CTAG2, CCL26 and ABCA 13.
9. The kit of claim 7 or 8, wherein the reagent for detecting the expression level of VSTM2L, TSPAN8, RDH10, PRODH, PITX2, ODC1, MASP1, KLHDC8A, GPRC5D, CTAG2, CCL26 and ABCA13 genes or proteins is a gene-specific primer, a gene-specific probe or an antibody.
10. The kit according to claim 7 or 8, characterized in that it comprises instructions bearing the following:
detecting log2(FPKM +1) values of VSTM2L, TSPAN8, RDH10, PRODH, PITX2, ODC1, MASP1, KLHDC8A, GPRC5D, CTAG2, CCL26, and ABCA13 gene expression levels in individuals or samples of laryngeal squamous cell carcinoma;
substituting the above values into the Score model Score (-0.7519 × VSTM2L) + (-0.7602 × TSPAN8) + (0.1142 × RDH10) + (0.1816 × PRODH) + (0.3597 × PITX2) + (0.0034 × ODC1) + (-0.3224 × MASP1) + (0.4007 × KLHDC8A) + (0.0877 × GPRC5D) + (0.1375 × CTAG2) + (-0.9765 × CCL26) + (0.4486 × ABCA13) +7.047 to calculate the Score;
if the Score is more than or equal to 0, the laryngeal squamous carcinoma individual or the sample is considered to have no ATM and/or ATR gene mutation, and the laryngeal squamous carcinoma individual is sensitive to radiotherapy; when Score <0, ATM and/or ATR gene mutations were present in the laryngeal squamous carcinoma individual or sample, who was not sensitive to radiation therapy.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111190928.7A CN113755596B (en) | 2021-10-13 | 2021-10-13 | Kit for detecting gene mutation of laryngeal squamous cell carcinoma radiotherapy sensitivity related gene ATM and ATR and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111190928.7A CN113755596B (en) | 2021-10-13 | 2021-10-13 | Kit for detecting gene mutation of laryngeal squamous cell carcinoma radiotherapy sensitivity related gene ATM and ATR and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN113755596A true CN113755596A (en) | 2021-12-07 |
| CN113755596B CN113755596B (en) | 2023-04-07 |
Family
ID=78799379
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202111190928.7A Active CN113755596B (en) | 2021-10-13 | 2021-10-13 | Kit for detecting gene mutation of laryngeal squamous cell carcinoma radiotherapy sensitivity related gene ATM and ATR and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113755596B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114452378A (en) * | 2022-01-20 | 2022-05-10 | 中山大学 | Application of RDH10 and/or prodrug thereof in preparation of medicines for treating and/or preventing diabetic myocardial damage |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102459638A (en) * | 2009-06-19 | 2012-05-16 | 默克专利有限公司 | Biomarkers and methods for determining efficacy of anti-egfr antibodies in cancer therapy |
| US20130165337A1 (en) * | 2011-12-22 | 2013-06-27 | Aveo Pharmaceuticals, Inc. | Identification of multigene biomarkers |
| CN110564851A (en) * | 2019-07-29 | 2019-12-13 | 浙江大学 | Group of genes for molecular typing of non-hyper-mutant rectal cancer and application thereof |
| US20210063398A1 (en) * | 2018-01-23 | 2021-03-04 | Duke University | Methods For Predicting Tumor Response To Immunotherapy |
| CN113151479A (en) * | 2021-05-11 | 2021-07-23 | 复旦大学附属中山医院 | Kit for detecting lung adenocarcinoma cell cycle progression pathway related gene mutation |
| CN113444793A (en) * | 2021-05-31 | 2021-09-28 | 复旦大学附属中山医院 | Kit for detecting lung adenocarcinoma antioxidant stress pathway related gene mutation |
-
2021
- 2021-10-13 CN CN202111190928.7A patent/CN113755596B/en active Active
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102459638A (en) * | 2009-06-19 | 2012-05-16 | 默克专利有限公司 | Biomarkers and methods for determining efficacy of anti-egfr antibodies in cancer therapy |
| US20130165337A1 (en) * | 2011-12-22 | 2013-06-27 | Aveo Pharmaceuticals, Inc. | Identification of multigene biomarkers |
| US20210063398A1 (en) * | 2018-01-23 | 2021-03-04 | Duke University | Methods For Predicting Tumor Response To Immunotherapy |
| CN110564851A (en) * | 2019-07-29 | 2019-12-13 | 浙江大学 | Group of genes for molecular typing of non-hyper-mutant rectal cancer and application thereof |
| CN113151479A (en) * | 2021-05-11 | 2021-07-23 | 复旦大学附属中山医院 | Kit for detecting lung adenocarcinoma cell cycle progression pathway related gene mutation |
| CN113444793A (en) * | 2021-05-31 | 2021-09-28 | 复旦大学附属中山医院 | Kit for detecting lung adenocarcinoma antioxidant stress pathway related gene mutation |
Non-Patent Citations (2)
| Title |
|---|
| XUE-KUI LIU ET AL.: ""Expression and clinical significance of SIAH in laryngeal squamous cell carcinoma"" * |
| 周学军等: ""喉鳞癌组织中SMG-1、ATM和P53的表达及临床意义"" * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114452378A (en) * | 2022-01-20 | 2022-05-10 | 中山大学 | Application of RDH10 and/or prodrug thereof in preparation of medicines for treating and/or preventing diabetic myocardial damage |
Also Published As
| Publication number | Publication date |
|---|---|
| CN113755596B (en) | 2023-04-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Tarantino et al. | ESMO expert consensus statements (ECS) on the definition, diagnosis, and management of HER2-low breast cancer | |
| Yang et al. | Metastasis predictive signature profiles pre-exist in normal tissues | |
| JP2008502908A (en) | Methods and systems related to liver disease | |
| Kostoulas et al. | Bayesian estimation of sensitivity and specificity of serum ELISA and faecal culture for diagnosis of paratuberculosis in Greek dairy sheep and goats | |
| CN115144599B (en) | Application of protein combination in preparation of kit for carrying out prognosis stratification on thyroid cancer of children, and kit and system thereof | |
| US11198912B2 (en) | Biomarkers for the diagnosis of lung cancers | |
| CN113755596B (en) | Kit for detecting gene mutation of laryngeal squamous cell carcinoma radiotherapy sensitivity related gene ATM and ATR and application thereof | |
| JP2018512160A (en) | Methods for lung cancer typing | |
| CN112522413A (en) | Biomarker for evaluating gastric cancer risk and application thereof | |
| CN112795648A (en) | Gastric cancer diagnostic product | |
| CN112746107A (en) | Gastric cancer related biomarkers and their use in diagnosis | |
| CN108588218B (en) | Serum miRNA combined minimally invasive detection kit | |
| US20170082632A1 (en) | Keratin 17 as a biomarker for head and neck cancers | |
| CN112481380B (en) | Marker for evaluating anti-tumor immunotherapy reactivity and prognosis survival of late bladder cancer and application thereof | |
| WO2019185864A1 (en) | Biomarkers for diabetes therapy | |
| CN113736888A (en) | Reagent, kit and method for detecting lung squamous carcinoma antioxidant stress drive pathway related gene mutation | |
| EP3752640A1 (en) | Methods for subtyping of bladder cancer | |
| CN115161398A (en) | Marker combination for colon cancer diagnosis or prognosis evaluation | |
| TW202303151A (en) | Biomarkers for determining an immuno-oncology response | |
| CN113265462A (en) | Gene related to gastric cancer and application thereof | |
| CN112575089A (en) | Application of gene in diagnosis of gastric cancer | |
| CN112725443A (en) | Biomarker combination and application thereof | |
| He et al. | Prognostic value of oral Epstein–Barr virus DNA load in locoregionally advanced nasopharyngeal carcinoma | |
| CN112680521A (en) | Product using gene as diagnostic marker and application thereof | |
| CN113444788B (en) | Glaucoma diagnostic product and application |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |